Q-omics provides the consensus-scored LRRC24 profile across patient tissues and cancer cell-line models. LRRC24 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LRRC24 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, LRRC24 RNA expression shows 11,898 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, BRCA, and ACC as cancer lineages where LRRC24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC24 survival associations across molecular data types. LRRC24 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC24 RNA expression–survival associations across cancer types. High LRRC24 expression shows unfavorable associations in COAD, ACC, CESC and TGCT, but favorable associations in HNSC and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LRRC24 RNA expression.
This table summarizes LRRC24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC24 shows lower tumor expression in COAD, STAD and KIRC and higher tumor expression in BRCA and LIHC. The BRCA box plot shows higher LRRC24 RNA expression in tumor versus normal tissue (log2 FC = +0.030, t-test p < 0.001).
This table shows molecular features associated with LRRC24 in patient tissues and cancer cell lines. In patient samples, LRRC24 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
